People with multiple sclerosis (MS) who are treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, although the absolute risk remains low. This is according to the first large population-based study in the field, led by researchers at Karolinska Institutet and published in JAMA Neurology.